Sanofi MenQuadfi wins EU approval for use in infants from six weeks
SNY•EU label extended for MenQuadfi
The European Commission extended the EU label for Sanofi’s MenQuadfi meningococcal vaccine to include infants from six weeks of age.
MenQuadfi was previously cleared for use from 12 months and older.
The broader indication targets invasive meningococcal disease caused by serogroups A, C, W, and Y.
The decision follows a positive CHMP opinion issued on June 25, 2026.
